Use of ACE inhibitors and ARBs in CKD

The Chronic Kidney Disease Solution™ By Shelly Manning It is an eBook that includes the most popular methods to care and manage kidney diseases by following the information provided in it. This easily readable eBook covers up various important topics like what is chronic kidney disease, how it is caused, how it can be diagnosed, tissue damages caused by chronic inflammation, how your condition is affected by gut biome, choices for powerful lifestyle and chronic kidney disease with natural tools etc.

The use of Angiotensin-Converting Enzyme (ACE) inhibitors and Angiotensin II Receptor Blockers (ARBs) in Chronic Kidney Disease (CKD) is a cornerstone of therapy, particularly in patients with proteinuria. These medications are commonly used because they help slow the progression of kidney disease by reducing intraglomerular pressure, which in turn reduces proteinuria and preserves kidney function. Here is a detailed overview:

Mechanism of Action:

ACE Inhibitors: These drugs inhibit the enzyme that converts angiotensin I to angiotensin II, a potent vasoconstrictor. By blocking this conversion, ACE inhibitors reduce the levels of angiotensin II, leading to vasodilation, reduced blood pressure, and decreased glomerular filtration pressure.
ARBs: ARBs block the angiotensin II receptors (specifically AT1 receptors), preventing angiotensin II from exerting its effects. This also leads to vasodilation and reduced blood pressure, with a similar effect on reducing glomerular pressure.

Benefits in CKD:

Reduction of Proteinuria: Both ACE inhibitors and ARBs are effective in reducing proteinuria, a key marker of kidney damage. The reduction in proteinuria is associated with a slower progression of CKD.
Blood Pressure Control: These drugs are particularly effective in lowering blood pressure, which is critical in preventing further kidney damage in CKD patients. Hypertension is a common complication in CKD, and controlling it is essential for slowing disease progression.
Protection Against Progression: Studies have shown that ACE inhibitors and ARBs can slow the progression of CKD, particularly in patients with diabetic nephropathy or significant proteinuria. They achieve this by reducing glomerular hyperfiltration and preventing the deleterious effects of angiotensin II on the kidneys.

Clinical Use:

First-Line Therapy: In patients with CKD, especially those with proteinuria, ACE inhibitors or ARBs are often first-line therapy. They are recommended by major guidelines, including those from the Kidney Disease: Improving Global Outcomes (KDIGO) organization.
Combination Therapy: It is generally not recommended to use ACE inhibitors and ARBs together due to the increased risk of hyperkalemia, hypotension, and worsening renal function without additional benefit in slowing CKD progression.
Dosage and Monitoring: Doses of ACE inhibitors and ARBs are titrated based on blood pressure and kidney function. Regular monitoring of serum creatinine and potassium levels is essential, as these drugs can cause hyperkalemia and a temporary increase in serum creatinine.

Adverse Effects:

Hyperkalemia: One of the most significant risks of ACE inhibitors and ARBs is hyperkalemia, which can be life-threatening if not managed properly. This risk is higher in patients with advanced CKD.
Worsening Renal Function: An initial increase in serum creatinine is expected and usually not concerning unless it is greater than 30% above baseline. However, significant worsening of renal function may necessitate dose reduction or discontinuation.
Angioedema (ACE inhibitors): Although rare, angioedema is a potentially serious side effect of ACE inhibitors. ARBs are generally considered safer in patients who have experienced angioedema with ACE inhibitors.

Special Considerations:

Diabetes and CKD: In diabetic patients with CKD, the use of ACE inhibitors or ARBs is particularly beneficial, as these patients are at high risk of developing nephropathy. These medications not only lower blood pressure but also provide additional kidney protection.
Advanced CKD: In patients with more advanced CKD (e.g., stage 4 or 5), the use of these medications requires careful consideration and close monitoring due to the higher risk of adverse effects, particularly hyperkalemia and significant reduction in GFR.

Contraindications:

Bilateral Renal Artery Stenosis: Use of ACE inhibitors and ARBs is contraindicated in patients with bilateral renal artery stenosis or in those with a single functioning kidney and renal artery stenosis, as they can precipitate acute kidney injury in these patients.
Pregnancy: These drugs are contraindicated during pregnancy due to the risk of fetal toxicity.

Conclusion:

ACE inhibitors and ARBs play a critical role in managing CKD, particularly in patients with proteinuria and hypertension. Their benefits in slowing disease progression and reducing cardiovascular risk outweigh their potential risks in most patients. However, careful patient selection, dose titration, and monitoring are essential to minimize adverse effects and optimize outcomes in CKD patients.